Advertisement

Maternal Use of Opiates or Opioid Analgesics and Infant Congenital Malformations

  • Bengt Källén
Chapter

Abstract

Although there are statements in literature on teratogenic effects of opioids including an increased risk of neural tube defects and of cardiac defects, these are based on retrospective studies of dubious validity. Most prospective data speak in favor of a low teratogenic effect of such drugs—even if unwanted effects of other nature can be obtained, notably after exposure during late pregnancy. It is likely that a weak teratogenic effect of tramadol exists, notably increasing the risk for pes equinovarus, but further data are needed. Also the risk for cardiovascular defects may be increased but again further data are needed. If possible tramadol should be avoided in early pregnancy but if exposure has occurred the individual risk must be regarded as low.

References

  1. Barrow MV, Souder DE. Propoxyphene and congenital malformations. JAMA. 1971;217:1551–2.CrossRefGoogle Scholar
  2. Broussard CS, Rasmussen S, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, Honein MA, for The National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(314):21–314.e11.Google Scholar
  3. Golden NL, King KC, Sokol RJ. Propoxyphene and acetaminophen. Possible effects on the fetus. Clin Pediatr. 1982;21:752–4.CrossRefGoogle Scholar
  4. Gouraud A, Beyens MN, Boyer M, Carlier P, Thompson MA, Garayt C, Bernard N, Vial T. First trimester exposure to tramadol: a prospective comparative study. Fundam Clin Pharmacol. 2010;24(Suppl. 1):90.Google Scholar
  5. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977.Google Scholar
  6. Interrante JD, Ailes EC, Lind JN, Anderka M, Feldkamp ML, Werler MM, Taylor LG, Trinidad J, Gilboa SM, Broussard CS, The National Birth Defects Prevention Study. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011. Ann Epidemiol. 2017;27:645–53.CrossRefGoogle Scholar
  7. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221–86.CrossRefGoogle Scholar
  8. Källén B, Reis M. Use of tramadol in early pregnancy and congenital malformation risk. Reprod Toxicol. 2015;58:246–51.CrossRefGoogle Scholar
  9. Källén B, Reis M. Ongoing pharmacological management of pain in pregnancy. Drugs. 2016;76:915–24.CrossRefGoogle Scholar
  10. Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:1253–61. Erratum Eur J Clin Pharmacol 2012;68:1689–1690.CrossRefGoogle Scholar
  11. Ringrose CAD. The hazard of neurotropic drugs in the fertile years. Can Med Assoc J. 1972;106:1058.PubMedPubMedCentralGoogle Scholar
  12. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol. 2013;122:838–44.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations